Skip to main content

External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.

Publication ,  Journal Article
Swaminathan, AC; Snyder, LD; Hong, H; Stevens, SR; Long, AS; Yanchenko, E; Qiu, Y; Liu, R; Zhang, H; Fischer, A; Burns, L; Wruck, LM; Palmer, SM
Published in: Am J Respir Crit Care Med
September 1, 2023

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which novel therapies are needed. External controls (ECs) could enhance IPF trial efficiency, but the direct comparability of ECs versus concurrent controls is unknown. Objectives: To develop IPF ECs by fit-for-purpose data standards to historical randomized clinical trial (RCT), multicenter registry (Pulmonary Fibrosis Foundation Patient Registry), and electronic health record (EHR) data and to evaluate endpoint comparability among ECs and the phase II RCT of BMS-986020. Methods: After data curation, the rate of change in FVC from baseline to 26 weeks among participants receiving BMS-986020 600 mg twice daily was compared with the BMS-placebo arm and ECs using mixed-effects models with inverse probability weights. Measurements and Main Results: At 26 weeks, the rates of change in FVC were -32.71 ml for BMS-986020 and -130.09 ml for BMS-placebo (difference, 97.4 ml; 95% confidence interval [CI], 24.6-170.2), replicating the original BMS-986020 RCT. RCT ECs showed treatment effect point estimates within the 95% CI of the original BMS-986020 RCT. Pulmonary Fibrosis Foundation Patient Registry ECs and EHR ECs experienced a slower rate of FVC decline compared with the BMS-placebo arm, resulting in treatment-effect point estimates outside of the 95% CI of the original BMS-986020 RCT. Conclusions: IPF ECs generated from historical RCT placebo arms result in comparable primary treatment effects to that of the original clinical trial, whereas ECs from real-world data sources, including registry or EHR data, do not. RCT ECs may serve as a potentially useful supplement to future IPF RCTs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

September 1, 2023

Volume

208

Issue

5

Start / End Page

579 / 588

Location

United States

Related Subject Headings

  • Vital Capacity
  • Treatment Outcome
  • Respiratory System
  • Lung
  • Information Sources
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Disease Progression
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Swaminathan, A. C., Snyder, L. D., Hong, H., Stevens, S. R., Long, A. S., Yanchenko, E., … Palmer, S. M. (2023). External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. Am J Respir Crit Care Med, 208(5), 579–588. https://doi.org/10.1164/rccm.202210-1947OC
Swaminathan, Aparna C., Laurie D. Snyder, Hwanhee Hong, Susanna R. Stevens, Alexander S. Long, Eric Yanchenko, Ying Qiu, et al. “External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.Am J Respir Crit Care Med 208, no. 5 (September 1, 2023): 579–88. https://doi.org/10.1164/rccm.202210-1947OC.
Swaminathan AC, Snyder LD, Hong H, Stevens SR, Long AS, Yanchenko E, et al. External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. Am J Respir Crit Care Med. 2023 Sep 1;208(5):579–88.
Swaminathan, Aparna C., et al. “External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.Am J Respir Crit Care Med, vol. 208, no. 5, Sept. 2023, pp. 579–88. Pubmed, doi:10.1164/rccm.202210-1947OC.
Swaminathan AC, Snyder LD, Hong H, Stevens SR, Long AS, Yanchenko E, Qiu Y, Liu R, Zhang H, Fischer A, Burns L, Wruck LM, Palmer SM. External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. Am J Respir Crit Care Med. 2023 Sep 1;208(5):579–588.

Published In

Am J Respir Crit Care Med

DOI

EISSN

1535-4970

Publication Date

September 1, 2023

Volume

208

Issue

5

Start / End Page

579 / 588

Location

United States

Related Subject Headings

  • Vital Capacity
  • Treatment Outcome
  • Respiratory System
  • Lung
  • Information Sources
  • Idiopathic Pulmonary Fibrosis
  • Humans
  • Disease Progression
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology